Sandoz Wants Amgen To Post $180M Bond For Losses

Law360, New York (May 13, 2015, 5:40 PM ET) -- Sandoz Inc. said Tuesday that Amgen Inc. should have to post a nearly $180 million bond to cover potential losses after the Federal Circuit temporarily blocked it from selling a copycat version of Amgen’s blockbuster anti-infection drug Neupogen.



Sandoz, a unit of Swiss drugmaker Novartis AG, said it would have made its biosimilar Zarxio available for sale Tuesday, if not for the injunction granted by the appeals court last week. The court ruled the product can’t be sold until it has resolved a dispute over information-sharing...

To view the full article, register now.